The Discounted Cash Flow (DCF) valuation of Hansa Biopharma AB (HNSA.ST) is (281.65) SEK. With the latest stock price at 30.74 SEK, the upside of Hansa Biopharma AB based on DCF is -1016.2%.
Based on the latest price of 30.74 SEK and our DCF valuation, Hansa Biopharma AB (HNSA.ST) is a sell. selling HNSA.ST stocks now will result in a potential gain of 1016.2%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 8.2% | 6.6% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (2,945.62) - (153.36) | (281.65) |
| Upside | -9682.4% - -598.9% | -1016.2% |